Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies by Ryotaro Ohkuma, Katsuaki Ieguchi, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Rie Onoue, Kazuyuki Hamada, Yutaro Kubota, Atsushi Horiike, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Junji Tsurutani, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada

Subjects: Get full text

Research progress of immune checkpoint inhibitors in the treatment of metastatic colorectal cancer by TU Juanjuan, JIN Zhiming

Subjects: Get full text

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma by Daoan Cheng, Weiqing Zhao, Rui Chen, Dong Li, Shuxian Tang, Cheng Fang, Mei Ji

Subjects: “…Anti-programmed death-1 (PD-1)…”
Get full text

Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients by Silvia C. Formenti, Rachael E. Hawtin, Neha Dixit, Erik Evensen, Percy Lee, Judith D. Goldberg, Xiaochun Li, Claire Vanpouille-Box, Dörthe Schaue, William H. McBride, Sandra Demaria

Subjects: Get full text

Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach by Panayotis Kaloyannidis, Eshrak Al Shaibani, Asif Moinnudin, Khalid Al Anezi, Hani Al Hashmi

Subjects: “…Allogeneic hematopoietic stem cell transplantation, Hodgkin lymphoma, programmed death-1 (PD-1) inhibitors…”
Get full text

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial by Wenjuan Tian, Yulan Ren, Jing Lu, Chuyu Jing, Wei Zhang, Haiming Li, Tingting Wang, Zhiguo Hou, Ting Yang, Wenqing Zhu, Yi Zhang, Boer Shan, Huijuan Yang, Xi Cheng, Huaying Wang

Subjects: Get full text

New targeted treatments for non-small-cell lung cancer – role of nivolumab by Zago G, Muller M, van den Heuvel M, Baas P

Subjects: Get full text

Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids by Mingbiao LI, Song XU, Haiyang FAN, Hongyi ZHANG, Ying LI, Yongwen LI, Minghui LIU, Hongyu LIU, Jun CHEN

Subjects: Get full text

Body mass index and serum alpha-fetoprotein level associated with PD1 expression and prognosis in patients with hepatocellular carcinoma by Lili Yang, Jili Wang, Linpeng Yao, Cheng Chen, Junhan Pan, Ling Peng, Feng Chen

Subjects: “…Programmed death 1(PD1)…”
Get full text

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints by Niki Karachaliou, Maria Gonzalez Cao, Cristina Teixidó, Santiago Viteri, Daniela Morales-Espinosa, Mariacarmela Santarpia, Rafael Rosell

Subjects: Get full text

Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience by Qin Yu, Haiyan Zhang, Yan Song, Chen Chen, Jin Chen, Junkang Shen

Subjects: Get full text

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer by Yuedi Zhang, Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen

Subjects: “…programmed death-1 (PD-1)…”
Get full text

Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy by Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani, Romina Esbati

Subjects: “…Programmed death-1 (PD-1)…”
Get full text

Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD by Suzuki Y, Inui N, Karayama M, Imokawa S, Yamada T, Yokomura K, Asada K, Kusagaya H, Kaida Y, Matsuda H, Koshimizu N, Toyoshima M, Masuda M, Hayakawa H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Suda T

Subjects: Get full text

B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles by Ion Antohe, Ion Antohe, Angela Dǎscǎlescu, Angela Dǎscǎlescu, Cǎtǎlin Dǎnǎilǎ, Cǎtǎlin Dǎnǎilǎ, Amalia Titieanu, Amalia Titieanu, Mihaela Zlei, Iuliu Ivanov, Adriana Sireteanu, Mariana Pavel, Petru Cianga

Subjects: Get full text

Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA by Rebeca Hid Cadena, Rosanne D. Reitsema, Minke G. Huitema, Yannick van Sleen, Kornelis S. M. van der Geest, Peter Heeringa, Annemieke M. H. Boots, Wayel H. Abdulahad, Wayel H. Abdulahad, Elisabeth Brouwer

Subjects: Get full text

CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis by Hui Yang, Qiannan Zhang, Miao Xu, Lei Wang, Xuewei Chen, Yongquan Feng, Yongning Li, Xin Zhang, Wenming Cui, Xudong Jia

Subjects: Get full text

CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B by Yuejiao Dong, Xuefen Li, Lu Zhang, Qiaoyun Zhu, Chunlei Chen, Jiaqi Bao, Yu Chen

Subjects: Get full text

PD-1-Mediated PI3K/Akt/mTOR, Caspase 9/Caspase 3 and ERK Pathways Are Involved in Regulating the Apoptosis and Proliferation of CD4+ and CD8+ T Cells During BVDV Infection in vitro by Yu Liu, Yu Liu, Yu Liu, Shanshan Liu, Chenhua Wu, Wenjing Huang, Bin Xu, Shuai Lian, Li Wang, Shan Yue, Nannan Chen, Zhanbo Zhu, Zhanbo Zhu, Zhanbo Zhu

Subjects: “…programmed death-1 (PD-1)…”
Get full text

IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS by E. L. Nasonov

Subjects: Get full text